Study S001018

A Phase 2, Randomized, Double-blind, Placebo-controlled, Study Evaluating the Effects of Aleniglipron (GSBR-1290) on Body Composition in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2)

ClinicalTrials.gov record

Registration

Registration: NCT07169942
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 71
Start: 2025-08-15
Primary completion: 2026-08
Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Conditions: Obesity, Overweight, or Chronic Weight Management
Interventions: DRUG:aleniglipron or placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Percent change in total body fat mass by DXA [Baseline and week 44]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.